Dry Age Related Macular Degeneration (AMD) Global Market Report 2025

The dry age related macular degeneration (AMD) market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.9 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period was driven by a rising aging population, an increased prevalence of chronic diseases, greater awareness of eye health, a growing number of clinical trials focused on dry AMD, and increasing demand for minimally invasive treatments.

The dry age related macular degeneration (AMD) market size is expected to see strong growth in the next few years. It will grow to $6.86 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The projected growth during the forecast period is driven by emerging novel therapies, increasing healthcare expenditure, greater utilization of laser photocoagulation therapy, advancements in genetic research, and a growing emphasis on personalized medicine. Key trends include innovations in diagnostic technologies, the rising adoption of teleophthalmology, the development of technologically advanced treatments, regulatory approvals, and new product launches.

The increasing geriatric population is expected to drive the growth of the dry age-related macular degeneration (AMD) market. The geriatric population refers to older adults, typically defined as individuals aged 65 and older. The rise in this demographic is driven by advancements in medical technology, better management of chronic diseases, increased life expectancy, and improved geriatric care. Dry AMD plays a crucial role in supporting the aging population by providing targeted treatments and management options aimed at slowing disease progression, preserving vision, and enhancing the quality of life for older individuals affected by the condition. For example, in June 2024, a report by the National Council on Aging, a US-based organization, stated that in 2022, there were approximately 57.8 million adults aged 65 and older, making up 17.3% of the total U.S. population, an increase from 16.9% in 2021. As a result, the growing geriatric population is expected to fuel the expansion of the dry AMD market.

Leading companies in the dry AMD market are focusing on developing advanced technologies and treatments, such as light delivery systems, to target and activate retinal cells, potentially slowing disease progression. Light delivery systems are designed to transmit light for therapeutic applications, particularly in medical treatments. For instance, in January 2024, LumiThera Inc., a US-based medical device company, introduced photobiomodulation (PBM) therapy for dry AMD through the Valeda Light Delivery System. This is the first FDA-authorized therapy aimed at addressing vision loss in patients with dry AMD, a condition with limited treatment options. LumiThera also launched the EUROLIGHT registry study to collect long-term patient data on Valeda system outcomes. The Valeda system uses a multi-wavelength light delivery method with three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive treatment can be administered through an open or closed eyelid and typically requires nine sessions over three to four weeks.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. This acquisition strengthens Astellas Pharma’s presence in the ophthalmology market and accelerates the development of innovative treatments for retinal diseases, improving patient outcomes worldwide. IVERIC Bio Inc., a US-based biotech company, specializes in the development of age-related macular degeneration drugs and related treatments, further enhancing Astellas Pharma’s research and development capabilities in the field.

Major players in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.

North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in dry age-related macular degeneration (AMD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dry age related macular degeneration (AMD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dry age-related macular degeneration (AMD) is a progressive eye condition that involves the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. Treatment options, including vitamins, nutritional supplements, and emerging pharmaceutical therapies, aim to manage and slow the disease's progression.

The main stages of dry AMD are early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early AMD is the initial stage of this common eye condition, which primarily affects older adults and causes changes in the retina, specifically the macula, responsible for central vision. It affects various age groups, including those above 40, 60, and 75 years. Treatment is administered through different routes, such as oral and injectable forms, and is utilized by various end users, including hospitals, clinics, diagnostic centers, and academic and research institutes.

The dry age related macular degeneration (AMD) market research report is one of a series of new reports that provides dry age related macular degeneration (AMD) market statistics, including dry age related macular degeneration (AMD) industry global market size, regional shares, competitors with a dry age related macular degeneration (AMD) market share, detailed dry age related macular degeneration (AMD) market segments, market trends and opportunities, and any further data you may need to thrive in the dry age related macular degeneration (AMD) industry. This dry age related macular degeneration (AMD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dry age related macular degeneration (AMD) market consists of sales of syfovre, zimura, visudyne, and alk-001. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.